Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 46Neoplasms 5Neoplasm Metastasis 5Metastatic Castration-Resistant Prostate Cancer 3Adenocarcinoma 3Recurrence 2Prostatic Neoplasms, Castration-Resistant 2Metastatic Hormone-sensitive Prostate Cancer 2Metastatic Castration-resistant Prostate Cancer 2Bulbo-Spinal Atrophy, X-Linked 2mCRPC 1Triple Negative Breast Neoplasms 1Solid Tumor 1Small Cell Lung Carcinoma 1Sleep Initiation and Maintenance Disorders 1Prostate Cancer Metastatic 1Prostate Adenocarcinoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy 1NSCLC Harboring NRG1 Fusion 1Metastatic Hormone Sensitive Prostate Cancer 1Metastatic Castration-resistant Prostate Neoplasms 1Lymphoma, Follicular 1Fatigue 1Depression 1Colorectal Neoplasms 1Castration Resistant Metastatic Prostate Cancer 1Castrate Sensitive Prostate Cancer 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1

Interventions

enzalutamide 2apalutamide 1abiraterone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Metastatic Hormone-sensitive Prostate Cancer × enzalutamide × 90 days × Clear all
NCT05901649 2026-06-05

ArtemisPRO

Janssen-Cilag Ltd.

Active not recruiting
504 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

NCT06991556 2026-06-02

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Novartis

Phase 2 Recruiting
150 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡